{
    "clinical_study": {
        "@rank": "85781", 
        "arm_group": [
            {
                "arm_group_label": "Alanyl-glutamine", 
                "arm_group_type": "Active Comparator", 
                "description": "Alanyl-glutamine, 44g, taken by mouth daily  for 10 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Glycine, 46g taken by mouth daily for 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the\n      treatment of C. difficile infection.  We hypothesize that alanyl-glutamine when given with\n      standard antibiotic treatment for C. difficile infection will decrease diarrhea, mortality\n      and recurrent disease in patients with history of malignancy."
        }, 
        "brief_title": "Efficacy Study of Alanyl-glutamine Supplementation for the Treatment of C. Difficile Infection", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Clostridium Difficile Infection", 
        "condition_browse": {
            "mesh_term": "Clostridium Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult of either gender, 18 years or older, with 1st episode C. difficile infection\n             (CDI)\n\n          -  Diarrhea associated with C. difficile positive stool assay\n\n          -  Within 48 hours of receiving either metronidazole for mild-moderate disease or\n             vancomycin for severe uncomplicated disease\n\n          -  Concurrent or history of malignancy\n\n          -  Admitted in the hospital at the time of enrollment\n\n          -  Ability to provide informed consent\n\n          -  Have an understanding of study procedures\n\n          -  Ability to comply with study procedures for the entire length of the study\n\n        Exclusion Criteria:\n\n          -  Hypotension or shock\n\n          -  Megacolon or moderate to severe ileus\n\n          -  Acute abdomen\n\n          -  Severe leukocytosis (WBC > 20,000 cells /\u00b5L)\n\n          -  Admission to intensive care unit on enrollment\n\n          -  Inability to tolerate oral medication\n\n          -  Other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal\n             disease)\n\n          -  Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)\n\n          -  Enrollment in another investigational drug trial\n\n          -  Currently receiving other alternative treatment for CDI (e.g. antibiotics other than\n             metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant)\n\n          -  History of multiple CDI\n\n          -  Pregnancy\n\n          -  Unavailable for follow-up visits\n\n          -  Life expectancy of < 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053350", 
            "org_study_id": "UVaHS-144404"
        }, 
        "intervention": [
            {
                "arm_group_label": "Alanyl-glutamine", 
                "intervention_name": "Alanyl-glutamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Clostridium difficile", 
            "glutamine", 
            "diarrhea", 
            "alanyl-glutamine"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "contact": {
                "email": "ca6t@virginia.edu", 
                "last_name": "Cirle A Warren, M.D.", 
                "phone": "434-924-9676"
            }, 
            "contact_backup": {
                "email": "asc9h@virginia.edu", 
                "last_name": "Ashley Chaplin, M.D.", 
                "phone": "434-283-3245"
            }, 
            "facility": {
                "address": {
                    "city": "Charlottesville", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "22908"
                }, 
                "name": "University of Virginia Health System"
            }, 
            "investigator": {
                "last_name": "Cirle A. Warren, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Alanyl-glutamine Supplementation of Standard Treatment of C. Difficile Infection in Patients With Malignancy: A Randomized, Double-blind, Placebo-controlled Trial", 
        "other_outcome": {
            "measure": "Fecal lactoferrin", 
            "safety_issue": "No", 
            "time_frame": "Change in fecal lactoferrin from Day 0 to Days 5 and 10 of treatment"
        }, 
        "overall_contact": {
            "email": "asc9h@virginia.edu", 
            "last_name": "Ashley Chaplin, M.D.", 
            "phone": "434-283-3245"
        }, 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "Cirle A. Warren, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to recurrent C. difficile infection", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months after enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053350"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Virginia", 
            "investigator_full_name": "Cirle Warren, MD", 
            "investigator_title": "Assistant Professor, Department of Medicine, Infectious Disease", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of diarrhea", 
                "safety_issue": "No", 
                "time_frame": "Up to day 10 of treatment"
            }, 
            {
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months after enrollment"
            }
        ], 
        "source": "University of Virginia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Virginia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}